Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Clin North Am ; 68(5): 961-976, 2021 10.
Article in English | MEDLINE | ID: mdl-34538306

ABSTRACT

Children usually present with milder symptoms of COVID-19 as compared with adults. Supportive care alone is appropriate for most children with COVID-19. Antiviral therapy may be required for those with severe or critical diseases. Currently there has been a rapid development of vaccines globally to prevent COVID-19 and several vaccines are being evaluated in children and adolescents. Currently, only the Pfizer-BioNTech messenger RNA vaccine is approved for emergency authorization use in the pediatric population ages 16 years and older.


Subject(s)
COVID-19 Vaccines/therapeutic use , COVID-19/prevention & control , Systemic Inflammatory Response Syndrome/prevention & control , Vaccines, Synthetic/therapeutic use , Adolescent , Child , Humans , Safety , Vaccines, Synthetic/adverse effects
2.
Expert Rev Clin Pharmacol ; 12(10): 965-971, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31526076

ABSTRACT

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder known to respond to amphetamine (AMPH). Multiple AMPH formulations have been developed during the past two decades and have focused mainly on extending the duration of effect. AMPH extended-release oral suspension, Dyanavel XR, (AMPH EROS) was developed to address the unmet needs of patients who have difficulty swallowing intact extended-release (ER) tablets and capsules. Areas covered: The pharmacokinetic profile of the AMPH EROS in children and adults is discussed along with the technology responsible for its release profile. Efficacy data from two clinical trials are presented and AMPH EROS is compared with other marketed AMPH ER formulations in the United States. Expert opinion: Multiple AMPH ER formulations that do not require ingestion of an intact tablet or capsule have been developed. Initial products allowed for sprinkling or dissolving of capsule contents. Recently, oral disintegrating tablets, chewable tablets, and oral suspensions have been marketed. Each formulation has positive attributes. Tablets may be more portable. However, as a suspension, AMPH EROS dosing can differ depending on daily requirements. Dose can also be titrated with a single prescription. Despite its convenience, AMPH EROS is a branded product, so price may be prohibitive for some patients.


Subject(s)
Amphetamine/administration & dosage , Attention Deficit Disorder with Hyperactivity/drug therapy , Central Nervous System Stimulants/administration & dosage , Administration, Oral , Adult , Amphetamine/pharmacokinetics , Central Nervous System Stimulants/pharmacokinetics , Child , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Liberation , Humans , Suspensions
SELECTION OF CITATIONS
SEARCH DETAIL
...